Board members

Uli Hacksell
Uli Hacksell
Chairman of the Board

Hacksell, born in 1950, has worked in the pharmaceutical industry and for biotechnology companies for 30 years. As CEO of San Diego-based ACADIA Pharmaceuticals (2000-2015), he led its development, from a private start-up company to a multi-billion-dollar public company, and also led the development of the first and only approved drug for psychosis in Parkinson’s patients. Since then, he has been CEO of Cerecor and Medivir. During the 1990s, Hacksell held senior positions within Astra’s R&D organisation, including as CEO of Astra Draco. Prior to that, he was a professor of organic chemistry at Uppsala University, where he also defended his thesis. He has published over 200 scientific articles. Hacksell is the chairman of the board at Medivir, and member of the board at InDex Pharmaceuticals Holding, Active Biotech and SynAct Pharma. Hacksell has been the Chairman of the board at Annexin since 2021.

Shareholding in the Company: 100 000 shares

Mårten Österlund
Mårten Österlund
Member of the Board

Österlund, born in 1957, has worked in the Swedish biotechnology and pharmaceutical industry. As head of business development and a member of the management team at established companies such as KaroBio AB (now KaroPharma), Affibody AB, Meda AB (now Viatris) for a total of more than 30 years, he has solid experience and knowledge within the field of life science. Österlund has been actively involved in and carried out a number of licensing purchases and sales, as well as purchases of products and companies, for example Rottapharm (purchase price SEK 21.2 billion). He has a background as a chemist, has a PhD in molecular biology at Uppsala University, and has carried out research in neurobiology at the Pasteur Institute in Paris. Österlund is a member of the board of directors at Pharma Way AB, Neobiomics AB and Unimedic Pharma Holding AB. Österlund has been a member of Annexin’s Board since 2021.

Shareholding in the Company: No shares

Carl-Fredrik Lindner
Carl-Fredrik Lindner
Member of the Board

Lindner, born in 1976, with a Master of Science from KTH Royal Institute of Technology, Stockholm, Sweden. Carl-Fredrik is the responsible Investment Manager at Lionpeak AB, Stockholm, Sweden. He has a background in Corporate Finance and worked with a Venture Capital fund, investing in Life Science. Lindner has been a member of Annexin’s board since 2017.

Shareholding in the Company: 140 000 shares and 60 000 share option rights serie TO3

Johan Frostegård
Johan Frostegård
Member of the Board

Professor Frostegård, born in 1959, is Head of Department of Immunology and Chronic Disease at the Institute of Environmental Medicine, Karolinska Institute, Stockholm. Professor Frostegård leads a group of 10 – 15 research workers. He is a specialist in Internal Medicine and Rheumatology and is Senior Consultant at the Institute of Emergency Healthcare at Karolinska University Hospital, Huddinge. Professor Frostegård is the inventor of around 20 patent applications, several granted and around 140 original scientific publications and several books. Frostegård has been a member of Annexin Pharmaceuticals board since 2016.

Shareholding in the Company: 2 873 296 indirectly, through Frostskog AB and Medirista AB (which own 2 369 296 and 504 000 shares in Annexin respectively) and 1 000 000 share option rights serie TO3 through Frostskog AB

 

Gisela Sitbon
Gisela Sitbon
Member of the Board

Sitbon, born in 1958, holds a Doctorate in Medical Sciences from Karolinska Institutet, Stockholm, Sweden and twenty-five years’ experience in the life science industry, over ten years in senior positions. Sitbon is member of the board at a number of companies, among others she is the chairman at Nanologica AB. Sitbon has been a member of Annexin’s board since 2017.

Shareholding in the Company: 21 000 shares and 9 000 share option rights serie TO3

Anthon Jahreskog
Member of the Board

Jahreskog, born in 1980, holds a Master’s degree in Financial Management and has previously been Chief Operating Officer, Fund Linked Products, Credit Suisse Investment bank, London. Jahreskog is a board member of BioGaia AB (publ), Infant Bacterial Therapeutics (IBT) AB and Fast Track Holdings Ltd. Jahreskog has been a board member of Annexin since 2022. Jahreskog is independent in relation to Annexin and its management as well as in relation to the company’s major shareholders.

Shareholding in the Company: 22 690 shares